Document is current
Any future updates will be listed below
-
Authors
Murata, Daiki https://orcid.org/0000-0002-4295-5046
Azuma, Koichi https://orcid.org/0000-0001-5040-5856
Murotani, Kenta https://orcid.org/0000-0003-0623-9365
Kawahara, Akihiko
Nishii, Yuuya
Tokito, Takaaki https://orcid.org/0000-0002-8429-2287
Sasada, Tetsuro
Hoshino, Tomoaki
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP19ae0101076)
- License Information
-
More Information
Article History
Received: 6 March 2024
Accepted: 14 July 2024
First Online: 5 September 2024
Declarations
:
: KA reports receiving personal fees from AstraZeneca, MSD, Bristol Myers Squibb, Ono Pharmaceutical, Takeda Pharmaceutical, Pfizer, and Chugai Pharmaceutical. TT reports receiving personal fees from AstraZeneca, Bristol Myers Squibb, MSD, Novartis, and Chugai Pharmaceutical. TS reports receiving personal fees from Chugai Pharmaceutical and Bristol Myers Squibb, and research funds from Taiho, and BrightPath Biotherapeutics. The remaining authors have no conflicts of interest to disclose.
: This study was conducted in accordance with the provisions of the Declaration of Helsinki and was approved by the Institutional Review Board of the Kurume University Hospital (IRB No 20100).
: Informed consent was obtained from all participants.
